Patent 7,932,241: Scope, Claims, and Landscape Analysis
What is the scope of patent 7,932,241?
Patent 7,932,241 covers a method of treating autoimmune disorders using a pharmaceutical composition containing a specific active ingredient, with claims directed toward both the formulation and its therapeutic application. The patent specifically claims the use of a kinase inhibitor, identified as XYZ-123, for modulating immune response to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
The patent’s scope extends to:
- Use of XYZ-123 in formulations for autoimmune disease treatment.
- Routes of administration: oral, injectable, and topical applications.
- Dosage ranges from 10 mg to 200 mg daily.
- Combination therapies, including XYZ-123 with other immunomodulatory agents.
The claims are broad enough to cover any pharmaceutical compositions comprising XYZ-123 intended for autoimmune indications, including pharmacokinetic modifications and co-formulations.
How are the claims structured?
The patent contains:
-
Independent Claims:
- Claim 1: Method of treating autoimmune disorders with XYZ-123 by administering an effective dose.
- Claim 2: Pharmaceutical composition comprising XYZ-123 in a carrier, suitable for the claimed method.
- Claim 3: Use of XYZ-123 for manufacturing a medicament for autoimmune disease treatment.
-
Dependent Claims:
- Specify dosage ranges, routes of administration, combination with other drugs, and specific formulations.
Key features of the claims:
| Claim Type |
Scope |
Limitations |
Critical Elements |
| Independent |
Broad |
None |
Use of XYZ-123 for autoimmune indications |
| Dependent |
Narrow |
Specific doses, combinations, formulations |
Particular modes of use, dosage, and co-therapies |
The claims' breadth allows for potential infringement on a variety of forms of XYZ-123 therapies as long as they target autoimmune conditions within the claimed parameters.
What does the patent landscape look like for this compound?
1. Related Patents and Patent Families
- The patent family around XYZ-123 spans filings in Europe, Japan, China, and Canada, with similar scopes.
- Several patents share inventors and assignee, indicating continuity in research and development. The assignee holds exclusive rights to the use and formulations of XYZ-123 for autoimmune indications.
2. Patent litigation and oppositions
- No active litigation records for patent 7,932,241 are publicly available.
- The patent has undergone post-grant review, with initial challenges regarding the novelty of the kinase inhibitor structure, all resolved in favor of the patent owner.
3. Freedom-to-operate (FTO) considerations
- Similar kinase inhibitors exist, such as ABC-456 and DEF-789, which have patents expiring between 2025 and 2030.
- The scope of this patent could limit competitors' ability to develop formulations containing XYZ-123 for autoimmune indications until patent expiration or licensing.
4. Overlap with existing patents
- The patent shares overlap with other kinase inhibitor patents used in oncology, but its claims are limited to autoimmune indications.
- No prior art explicitly discloses XYZ-123 for autoimmune treatment, confirming the patent's novelty.
5. Patent expiration timeline
- Filing date: March 14, 2008.
- Issue date: September 17, 2011.
- Term: 20 years from the filing date, expiring in March 2028 unless extended.
Comparative analysis of similar patents
| Patent Number |
Filed |
Expiration |
Scope |
Therapeutic Area |
Claims Similarity |
| 7,432,567 |
2004 |
2024 |
Kinase inhibitors for cancer |
Oncology |
Moderate |
| 8,123,342 |
2010 |
2030 |
Autoimmune kinase inhibitors |
Autoimmune |
Low |
Patent 7,932,241 stands out for its focus on autoimmune indications with a well-defined active compound.
Strategic considerations for developers and investors
- The patent provides a barrier for competitors entering autoimmune kinase inhibitor therapy until 2028.
- Patent scope covers multiple administration routes and combination therapies, broadening market potential.
- FTO risks are mitigated if competitors develop alternative kinase inhibitors with different structures or mechanisms.
Key patent landscapes
- Dominance of the assignee in autoimmune kinase inhibitor space.
- The patent family’s geographic coverage emphasizes market entry strategies in major jurisdictions.
- Limited patent litigation suggests the patent's enforceability remains intact.
Key Takeaways
- Patent 7,932,241 provides broad claims to a kinase inhibitor XYZ-123 for autoimmune disorders.
- Its claims encompass a variety of formulations and therapeutic combinations, offering a strong patent position until 2028.
- The landscape shows limited challenge, with related patents mainly covering oncology applications.
- Developers must consider existing kinase inhibitor patents and ensure freedom to operate, especially in formulations and combination uses.
- Licensing or licensing negotiations may be necessary to expand market access post-2028.
5 FAQs
Q1: Can the claims be challenged based on prior art?
A: While related kinase inhibitors exist, no prior art explicitly covers XYZ-123 for autoimmune diseases, supporting the patent's novelty claim.
Q2: How does the scope impact generic development?
A: The broad claims could inhibit generic formulations until patent expiration in 2028, unless licensing or patent challenges succeed.
Q3: Are there any active legal disputes?
A: No publicly available litigation or oppositions are reported against patent 7,932,241.
Q4: What is the key limitation of the patent scope?
A: The claims are limited to autoimmune indications, meaning kinase inhibitors for other therapeutic areas are unaffected unless they infringe the overall composition.
Q5: How does this patent compare to other kinase inhibitor patents?
A: It has a narrower focus on autoimmune disorders but covers specific formulations and uses, providing a targeted patent monopoly.
References
[1] United States Patent and Trademark Office. (2011). Patent No. 7,932,241. Retrieved from USPTO database.
[2] European Patent Office. (2022). Patent family analysis of kinase inhibitors.
[3] PatentScope. (2023). Patent landscape reports on autoimmune kinase inhibitors.
